Imaging Hepatocellular Carcinoma With (68)Ga-Citrate PET: First Clinical Experience

por Mari Aparici, Carina, Behr, Spencer C., Seo, Youngho, Kelley, R. Kate, Corvera, Carlos, Gao, Kenneth T., Aggarwal, Rahul, Evans, Michael J.
Publicado 2017

Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve

por Fidelman, Nicholas, Johanson, Curt, Kohi, Maureen P, Kolli, K Pallav, Kohlbrenner, Ryan M, Lehrman, Evan D, Taylor, Andrew G, Kelley, R Kate, Yao, Francis Y, Roberts, John P, Kerlan, Robert K
Publicado 2019

A Real‐World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET‐HCC

por Cabrera, Roniel, Singal, Amit G., Colombo, Massimo, Kelley, R. Kate, Lee, Hannah, Mospan, Andrea R., Meyer, Tim, Newell, Pippa, Parikh, Neehar D., Sangro, Bruno, Reddy, K. Rajender, Watkins, Stephanie, Zink, Richard C., Di Bisceglie, Adrian M.
Publicado 2020

A single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS

por McMahon, Mary, Contreras, Adrian, Holm, Mikael, Uechi, Tamayo, Forester, Craig M, Pang, Xiaming, Jackson, Cody, Calvert, Meredith E, Chen, Bin, Quigley, David A, Luk, John M, Kelley, R Kate, Gordan, John D, Gill, Ryan M, Blanchard, Scott C, Ruggero, Davide
Publicado 2019

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial

por Zhu, Andrew X., Macarulla, Teresa, Javle, Milind M., Kelley, R. Kate, Lubner, Sam J., Adeva, Jorge, Cleary, James M., Catenacci, Daniel V. T., Borad, Mitesh J., Bridgewater, John A., Harris, William P., Murphy, Adrian G., Oh, Do-Youn, Whisenant, Jonathan R., Lowery, Maeve A., Goyal, Lipika, Shroff, Rachna T., El-Khoueiry, Anthony B., Chamberlain, Christina X., Aguado-Fraile, Elia, Choe, Sung, Wu, Bin, Liu, Hua, Gliser, Camelia, Pandya, Shuchi S., Valle, Juan W., Abou-Alfa, Ghassan K.
Publicado 2021